• RSS MedPageToday.com – medical news plus CME for physicians

    • Post-IO Lenvima-Keytruda Combo Highly Active in mRCC
      ]]>(MedPage Today) — MIAMI — Combination of VEGF inhibition plus an immune checkpoint inhibitor produced responses in nearly two-thirds of metastatic renal cell carcinoma (mRCC) patients who had already progressed on an immunotherapy (IO), interim…
  • Personalized attention, readily available appointment times, consistent follow-up, professional and courteous services are just a few of the added benefits you will experience with Dr. Oganessian.

  • Personalized Care

    Dr. Oganessian will personally allocate the time necessary to make sure all of your questions and concerns are addressed and that you walk out of the appointment feeling unrushed and satisfied and with a smile.